Estimated Thresholds of Minimum Necessary Adherence for Effective Treatment with Direct Oral Anticoagulants – A Retrospective Cohort Study in Health Insurance Claims Data

References

• Raparelli V, Proietti M, Cangemi R, Lip GY, Lane DA, Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2017;117(2):209–218. doi:10.1160/TH16-10-0757
   PubMed Web of Science ®Google Scholar
• Baumgartner PC, Haynes RB, Hersberger KE, Arnet I. A systematic review of medication adherence thresholds dependent of clinical outcomes. Front Pharmacol. 2018;9:1290. doi:10.3389/fphar.2018.01290
   PubMed Web of Science ®Google Scholar
• Walsh CA, Cahir C, Tecklenborg S, Byrne C, Culbertson MA, Bennett KE. The association between medication non-adherence and adverse health outcomes in ageing populations: a systematic review and meta-analysis. Br J Clin Pharmacol. 2019;85(11):2464–2478. doi:10.1111/bcp.14075
   PubMed Web of Science ®Google Scholar
• Shore S, Carey EP, Turakhia MP, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J. 2014;167(6):810–817. doi:10.1016/j.ahj.2014.03.023
   PubMed Web of Science ®Google Scholar
• Ruff C, Koukalova L, Haefeli WE, Meid AD. The role of adherence thresholds for development and performance aspects of a prediction model for direct oral anticoagulation adherence. Front Pharmacol. 2019;10:113. doi:10.3389/fphar.2019.00113
   Web of Science ®Google Scholar
• Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8(1):e016982. doi:10.1136/bmjopen-2017-016982
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15(12):1003–1008. doi:10.1007/s00198-004-1652-z
   PubMed Web of Science ®Google Scholar
• Doro P, Benko R, Kosik E, Matuz M, Toth K, Soos G. Utilization of oral antihyperglycemic drugs over a 7-year period (1998-2004) in a Hungarian population and adherence to drug therapy. Eur J Clin Pharmacol. 2005;61(12):893–897. doi:10.1007/s00228-005-0031-9
   Web of Science ®Google Scholar
• Hansen RA, Farley JF, Droege M, Maciejewski ML. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005. Clin Ther. 2010;32(7):1308–1319. doi:10.1016/j.clinthera.2010.07.011
   PubMed Web of Science ®Google Scholar
• Hurtado-Navarro I, Garcia-Sempere A, Rodriguez-Bernal C, Santa-Ana-Tellez Y, Peiro S, Sanfelix-Gimeno G. Estimating adherence based on prescription or dispensation information: impact on thresholds and outcomes. A real-world study with atrial fibrillation patients treated with oral anticoagulants in Spain. Front Pharmacol. 2018;9:1353. doi:10.3389/fphar.2018.01353
   Web of Science ®Google Scholar
• Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303–2310. doi:10.1185/03007990903126833
   PubMed Web of Science ®Google Scholar
• Wu JR, Moser DK, De Jong MJ, et al. Defining an evidence-based cutpoint for medication adherence in heart failure. Am Heart J. 2009;157(2):285–291. doi:10.1016/j.ahj.2008.10.001
   PubMed Web of Science ®Google Scholar
• Mukherjee D, Patil CG. Epidemiology and the global burden of stroke. World Neurosurg. 2011;76(6 Suppl):S85–90. doi:10.1016/j.wneu.2011.07.023
   PubMed Web of Science ®Google Scholar
• Collaborators GBDS. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(5):439–458. doi:10.1016/S1474-4422(19)30034-1
   PubMed Web of Science ®Google Scholar
• Godwin KM, Wasserman J, Ostwald SK. Cost associated with stroke: outpatient rehabilitative services and medication. Top Stroke Rehabil. 2011;18(Suppl 1):676–684. doi:10.1310/tsr18s01-676
   Web of Science ®Google Scholar
• Rajsic S, Gothe H, Borba HH, et al. Economic burden of stroke: a systematic review on post-stroke care. Eur J Health Econ. 2019;20(1):107–134. doi:10.1007/s10198-018-0984-0
   PubMed Web of Science ®Google Scholar
• Kolominsky-Rabas PL, Heuschmann PU, Marschall D, et al. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen stroke project. Stroke. 2006;37(5):1179–1183. doi:10.1161/01.STR.0000217450.21310.90
   Web of Science ®Google Scholar
• Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69(23):2779–2790. doi:10.1016/j.jacc.2017.03.600
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Shrader P, Thomas L, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol. 2016;68(24):2597–2604. doi:10.1016/j.jacc.2016.09.966
   PubMed Web of Science ®Google Scholar
• Santos J, Antonio N, Rocha M, Fortuna A. Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review. Br J Clin Pharmacol. 2020;86(3):533–547. doi:10.1111/bcp.14127
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Shrader P, Pieper K, et al. Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (the outcomes registry for better informed treatment of atrial fibrillation II). J Am Heart Assoc. 2018;7. doi:10.1161/JAHA.117.007633
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–1457. doi:10.1016/S0140-6736(07)61602-X
   PubMed Web of Science ®Google Scholar
• Lamberts M, Staerk L, Olesen JB, et al. Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patients. J Am Heart Assoc. 2017;6:2. doi:10.1161/JAHA.116.004517
   Web of Science ®Google Scholar
• Paschke LM, Klimke K, Altiner A, von Stillfried D, Schulz M. Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study. BMC Med. 2020;18(1):254. doi:10.1186/s12916-020-01695-7
   PubMed Web of Science ®Google Scholar
• Dima AL, Dediu D. Computation of adherence to medication and visualization of medication histories in R with AdhereR: towards transparent and reproducible use of electronic healthcare data. PLoS One. 2017;12(4):e0174426. doi:10.1371/journal.pone.0174426
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272. doi:10.1378/chest.09-1584
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139. doi:10.1097/01.mlr.0000182534.19832.83
   PubMed Web of Science ®Google Scholar
• van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009;47(6):626–633. doi:10.1097/MLR.0b013e31819432e5
   PubMedGoogle Scholar
• Cox DR. Regression models and life tables (with discussion). J Royal Stat Soc B. 1972;34:187–220.
   Web of Science ®Google Scholar
• Royston P, Altman DG. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling (with discussion). Appl Stat. 1994;43(3):429–467. doi:10.2307/2986270
   Web of Science ®Google Scholar
• Ritz C, Baty F, Streibig JC, Gerhard D. Dose-response analysis using R. PLoS One. 2015;10(12):e0146021. doi:10.1371/journal.pone.0146021
   PubMed Web of Science ®Google Scholar
• Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–35. doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3
   PubMed Web of Science ®Google Scholar
• Morawski K, Ghazinouri R, Krumme A, et al. Association of a smartphone application with medication adherence and blood pressure control: the MedISAFE-BP randomized clinical trial. JAMA Intern Med. 2018;178(6):802–809. doi:10.1001/jamainternmed.2018.0447
   PubMed Web of Science ®Google Scholar
• Reidel K, Tamblyn R, Patel V, Huang A. Pilot study of an interactive voice response system to improve medication refill compliance. BMC Med Inform Decis Mak. 2008;8(1):46. doi:10.1186/1472-6947-8-46
   PubMed Web of Science ®Google Scholar
• Huang D, Sangthong R, McNeil E, et al. Effects of a phone call intervention to promote adherence to antiretroviral therapy and quality of life of HIV/AIDS patients in Baoshan, China: a randomized controlled trial. AIDS Res Treat. 2013;2013:580974.
   PubMedGoogle Scholar
• Hacihasanoğlu R, Gözüm S. The effect of patient education and home monitoring on medication compliance, hypertension management, healthy lifestyle behaviours and BMI in a primary health care setting. J Clin Nurs. 2011;20(5–6):692–705. doi:10.1111/j.1365-2702.2010.03534.x
   Web of Science ®Google Scholar
• Fitzpatrick C, Gillies C, Seidu S, et al. Effect of pragmatic versus explanatory interventions on medication adherence in people with cardiometabolic conditions: a systematic review and meta-analysis. BMJ Open. 2020;10(7):e036575. doi:10.1136/bmjopen-2019-036575
   PubMed Web of Science ®Google Scholar
• McHorney CA, Ashton V, Laliberte F, et al. Adherence to rivaroxaban compared with other oral anticoagulant agents among patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2017;23(9):980–988. doi:10.18553/jmcp.2017.23.9.980
   PubMed Web of Science ®Google Scholar
• Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention for newly diagnosed and treatment-naive atrial fibrillation patients: an update using 2013-2014 data. J Manag Care Spec Pharm. 2017;23(9):958–967. doi:10.18553/jmcp.2017.23.9.958
   Web of Science ®Google Scholar
• Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naive nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2016;22(11):1319–1329. doi:10.18553/jmcp.2016.22.11.1319
   PubMedGoogle Scholar
• Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (randomized evaluation of long-term anticoagulation therapy). J Am Coll Cardiol. 2014;63(4):321–328. doi:10.1016/j.jacc.2013.07.104
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2288–2295. doi:10.1016/S0140-6736(14)61943-7
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang X, Liu X, et al. Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis. Eur J Epidemiol. 2021;36(8):793–812. doi:10.1007/s10654-021-00751-7
   PubMed Web of Science ®Google Scholar
• Almutairi AR, Zhou L, Gellad WF, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses. Clin Ther. 2017;39(7):1456–1478.e36. doi:10.1016/j.clinthera.2017.05.358
   PubMed Web of Science ®Google Scholar
• Graham DJ, Baro E, Zhang R, et al. Comparative stroke, bleeding, and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132(5):596–604 e11. doi:10.1016/j.amjmed.2018.12.023
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49(12):2933–2944. doi:10.1161/STROKEAHA.118.020232
   PubMed Web of Science ®Google Scholar
• Marietta M, Banchelli F, Pavesi P, et al. Direct oral anticoagulants vs non-vitamin K antagonist in atrial fibrillation: a prospective, propensity score adjusted cohort study. Eur J Intern Med. 2019;62:9–16. doi:10.1016/j.ejim.2018.12.010
   Web of Science ®Google Scholar
• Nielsen PB, Skjoth F, Sogaard M, Kjaeldgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510. doi:10.1136/bmj.j510
   PubMed Web of Science ®Google Scholar
• Staerk L, Gerds TA, Lip GYH, et al. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. J Intern Med. 2018;283(1):45–55. doi:10.1111/joim.12683
   Web of Science ®Google Scholar
• Coleman CI, Peacock WF, Bunz TJ, Alberts MJ. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack. Stroke. 2017;48(8):2142–2149. doi:10.1161/STROKEAHA.117.017474
   PubMed Web of Science ®Google Scholar
• Borne RT, O’Donnell C, Turakhia MP, et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. BMC Cardiovasc Disord. 2017;17(1):236. doi:10.1186/s12872-017-0671-6
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Cea Soriano L, Munk Hald S, et al. Discontinuation of oral anticoagulation in atrial fibrillation and risk of ischaemic stroke. Heart. 2020. doi:10.1136/heartjnl-2020-317887
   Web of Science ®Google Scholar
• Ihle P, Krueger K, Schubert I, et al. Comparison of different strategies to measure medication adherence via claims data in patients with chronic heart failure. Clin Pharmacol Ther. 2019;106(1):211–218. doi:10.1002/cpt.1378
   Web of Science ®Google Scholar
• Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105–116. doi:10.1016/s0895-4356(96)00268-5z
   PubMed Web of Science ®Google Scholar